Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients

Cancer Genetics

Volumn 205, Issue 4, 2012, Pages 190-191

  Alonso Dominguez, Juan Manuel ^a   Tenorio, Maria ^a   Velasco, Diego ^a   Abalo, Lorena ^a   Lozano, Sara ^a   Villarrubia, Jesus ^a   López Jimenez, Javier ^a   Grande, Silvia ^b   Ayala, Rosa ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR MARKER; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; BLOOD CYTOLOGY; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLOR ULTRASOUND FLOWMETRY; CONSOLIDATION CHEMOTHERAPY; DIAGNOSTIC VALUE; DISEASE MARKER; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; INDUCTION CHEMOTHERAPY; LETTER; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; BLOOD; BONE MARROW; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; BONE MARROW; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; WT1 PROTEINS; YOUNG ADULT;

EID: 84862748811     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.02.008     Document Type: Letter

References (9)

1. Menssen H.D., Renkl H.J., Entezami M., et al. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997, 89:3486-3487.
2. Maurer U., Weidmann E., Karakas T., et al. Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 1997, 90:4230-4232.
3. Cilloni D., Renneville A., Hermitte F., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009, 27:5195-5201.
4. Inoue K., Sugiyama H., Ogawa H., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994, 84:3071-3079.
5. Inoue K., Ogawa H., Sonoda Y., et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997, 89:1405-1412.
6. Buccisano F., Maurillo L., Del Principe M.I., et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2011, 119:332-341.
7. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339:1649-1656.
8. Lowenberg B. Strategies in the treatment of acute myeloid leukemia. Haematologica 2004, 89:1029-1032.
9. Kreuzer K.A., Saborowski A., Lupberger J., et al. Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001, 114:313-318.